NASDAQ:GOSS Gossamer Bio (GOSS) Stock Price, News & Analysis $0.90 -0.01 (-1.10%) (As of 09/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Gossamer Bio alerts: Email Address About Gossamer Bio Stock (NASDAQ:GOSS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Gossamer Bio alerts:Sign Up Key Stats Today's Range$0.89▼$0.9450-Day Range$0.79▼$1.2552-Week Range$0.45▼$1.60Volume589,761 shsAverage Volume1.57 million shsMarket Capitalization$203.30 millionP/E RatioN/ADividend YieldN/APrice Target$9.20Consensus RatingBuy Company OverviewGossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Read More… Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Gossamer Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 94th PercentileGossamer Bio scored higher than 94% of companies evaluated by MarketBeat, and ranked 54th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGossamer Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGossamer Bio has only been the subject of 3 research reports in the past 90 days.Read more about Gossamer Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Gossamer Bio are expected to decrease in the coming year, from ($0.33) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGossamer Bio has a P/B Ratio of 3.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Gossamer Bio's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.01% of the outstanding shares of Gossamer Bio have been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Gossamer Bio has recently decreased by 5.22%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.67 Percentage of Shares Shorted4.01% of the outstanding shares of Gossamer Bio have been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Gossamer Bio has recently decreased by 5.22%, indicating that investor sentiment is improving significantly. News and Social Media3.9 / 5News Sentiment0.93 News SentimentGossamer Bio has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Gossamer Bio this week, compared to 2 articles on an average week.Search Interest7 people have searched for GOSS on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows6 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have bought 19,696.66% more of their company's stock than they have sold. Specifically, they have bought $249,240.00 in company stock and sold $1,259.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gossamer Bio's insider trading history. Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GOSS Stock News HeadlinesGossamer Bio (GOSS) Receives a Buy from OppenheimerSeptember 16 at 8:03 PM | markets.businessinsider.com3 Penny Stocks To Buy With Just $50September 15 at 7:54 AM | 247wallst.comCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. September 17, 2024 | True Gold Republic (Ad)Gossamer Bio Has One More Shot On Goal And Is Not Likely To MissSeptember 10, 2024 | seekingalpha.comGossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024August 27, 2024 | stockhouse.comAnalysts Just Made A Notable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) ForecastsAugust 21, 2024 | finance.yahoo.comWhat It Takes to Perform Brain SurgeryAugust 16, 2024 | msn.comWith 73% institutional ownership, Gossamer Bio, Inc. (NASDAQ:GOSS) is a favorite amongst the big gunsAugust 16, 2024 | finance.yahoo.comSee More Headlines GOSS Stock Analysis - Frequently Asked Questions How have GOSS shares performed this year? Gossamer Bio's stock was trading at $0.9125 at the beginning of 2024. Since then, GOSS stock has decreased by 1.5% and is now trading at $0.8987. View the best growth stocks for 2024 here. How were Gossamer Bio's earnings last quarter? Gossamer Bio, Inc. (NASDAQ:GOSS) announced its earnings results on Monday, August, 12th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.23 by $0.01. The firm had revenue of $95.84 million for the quarter, compared to analysts' expectations of $160 million. When did Gossamer Bio IPO? Gossamer Bio (GOSS) raised $230 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO. Who are Gossamer Bio's major shareholders? Gossamer Bio's top institutional investors include NEA Management Company LLC (8.00%), Millennium Management LLC (2.47%), Acadian Asset Management LLC (1.59%) and Marshall Wace LLP (1.47%). Insiders that own company stock include Faheem Hasnain, Richard Aranda, Bryan Giraudo, Laura Carter and Caryn Peterson. View institutional ownership trends. How do I buy shares of Gossamer Bio? Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC) and NVIDIA (NVDA). Company Calendar Last Earnings8/12/2024Today9/17/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GOSS CUSIPN/A CIK1728117 Webwww.gossamerbio.com Phone(858) 684-1300FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Stock Price Target$9.20 High Stock Price Target$15.00 Low Stock Price Target$4.00 Potential Upside/Downside+922.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-179,820,000.00 Net MarginsN/A Pretax Margin-79.73% Return on Equity-117.33% Return on Assets-25.02% Debt Debt-to-Equity Ratio2.42 Current Ratio8.21 Quick Ratio8.21 Sales & Book Value Annual Sales$95.84 million Price / Sales2.12 Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book3.21Miscellaneous Outstanding Shares226,219,000Free Float214,908,000Market Cap$203.57 million OptionableOptionable Beta1.95 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:GOSS) was last updated on 9/17/2024 by MarketBeat.com Staff From Our PartnersSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredThe #1 Altcoin for September 2024With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election M...Paradigm Press | SponsoredJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.